Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53

被引:176
作者
Dayal, Saurabh [1 ]
Sparks, Alison [1 ]
Jacob, Jimmy [1 ]
Allende-Vega, Nerea [1 ]
Lane, David P. [1 ]
Saville, Mark K. [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, CR UK Cell Transformat Res Grp, Dundee DD1 9SY, Scotland
关键词
PROTEASOME INHIBITOR BORTEZOMIB; UBIQUITIN-CONJUGATING ENZYMES; PROTEIN-DEGRADATION; TUMOR-CELLS; MDM2; CHAINS; ISOPEPTIDASE; BINDING; SUBUNIT; SYSTEM;
D O I
10.1074/jbc.M805871200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Both p53 and its repressor Mdm2 are subject to ubiquitination and proteasomal degradation. We show that knockdown of the deubiquitinating enzyme USP5 (isopeptidase T) results in an increase in the level and transcriptional activity of p53. Suppression of USP5 stabilizes p53, whereas it has little or no effect on the stability of Mdm2. This provides a mechanism for transcriptional activation of p53. USP5 knockdown interferes with the degradation of ubiquitinated p53 rather than attenuating p53 ubiquitination. In vitro studies have shown that a preferred substrate for USP5 is unanchored polyubiquitin. Consistent with this, we observed for the first time in a mammalian system that USP5 makes a major contribution to Lys-48-linked polyubiquitin disassembly and that suppression of USP5 results in the accumulation of unanchored polyubiquitin chains. Ectopic expression of a C-terminal mutant of ubiquitin (G75A/G76A), which also causes the accumulation of free polyubiquitin, recapitulates the effects of USP5 knockdown on the p53 pathway. We propose a model in which p53 is selectively stabilized because the unanchored polyubiquitin that accumulates after USP5 knockdown is able to compete with ubiquitinated p53 but not with Mdm2 for proteasomal recognition. This raises the possibility that there are significant differences in proteasomal recognition of p53 and Mdm2. These differences could be exploited therapeutically. Our study reveals a novel mechanism for regulation of p53 and identifies USP5 as a potential target for p53 activating therapeutic agents for the treatment of cancer.
引用
收藏
页码:5030 / 5041
页数:12
相关论文
共 81 条
[1]
Amerik AY, 1997, EMBO J, V16, P4826
[2]
MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination [J].
Badciong, JC ;
Haas, AL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (51) :49668-49675
[3]
Surface hydrophobic residues of multiubiquitin chains essential for proteolytic targeting [J].
Beal, R ;
Deveraux, Q ;
Xia, G ;
Rechsteiner, M ;
Pickart, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (02) :861-866
[4]
Hypophosphorylation of Mdm2 augments p53 stability [J].
Blattner, C ;
Hay, T ;
Meek, DW ;
Lane, DP .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (17) :6170-6182
[5]
DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site [J].
Blaydes, JP ;
Hupp, TR .
ONCOGENE, 1998, 17 (08) :1045-1052
[6]
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy [J].
Boccadoro, Mario ;
Morgan, Gareth ;
Cavenagh, Jamie .
CANCER CELL INTERNATIONAL, 2005, 5 (1)
[7]
Regulation of Pax3 by proteasomal degradation of monoubiquitinated protein in skeletal muscle progenitors [J].
Boutet, Stephane C. ;
Disatnik, Marie-Helene ;
Chan, Lauren S. ;
Iori, Kevin ;
Rando, Thomas A. .
CELL, 2007, 130 (02) :349-362
[8]
A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway [J].
Brignone, C ;
Bradley, KE ;
Kisselev, AF ;
Grossman, SR .
ONCOGENE, 2004, 23 (23) :4121-4129
[9]
Brooks CL, 2004, CELL CYCLE, V3, P895
[10]
A system for stable expression of short interfering RNAs in mammalian cells [J].
Brummelkamp, TR ;
Bernards, R ;
Agami, R .
SCIENCE, 2002, 296 (5567) :550-553